Doxorubicin for treatment of histiocytic sarcoma in dogs: 31 cases (2003-2017).

Abstract

OBJECTIVE:

To evaluate the efficacy of doxorubicin for treatment of histiocytic sarcoma (HS) in dogs, whether administered as the sole treatment or as an adjunct to surgery or radiation therapy.

ANIMALS:

31 client-owned dogs with localized or disseminated HS examined between 2003 and 2017.

PROCEDURES:

Medical records were reviewed retrospectively, and data were collected. The Kaplan-Meier method was used to estimate time-to-progression from the date of first doxorubicin administration and survival time from initial diagnosis. Factors that could be associated with poorer outcomes with doxorubicin treatment were analyzed with log-rank tests.

RESULTS:

The objective response rate (ORR) was 26%. When stratified by disease status, dogs with localized and disseminated forms experienced 43% and 21% ORRs, respectively. Median time to progression after initiating doxorubicin treatment (n = 30 dogs) was 42 days. Median survival time from initial diagnosis to death (n = 29 dogs) was 169 days. Complete responses were obtained in only 2 dogs that had localized disease and received multimodality therapy.

CLINICAL RELEVANCE:

Benefits of doxorubicin administration in canine HS are modest, with a limited ORR and delay in tumor progression, and are comparable to effects attained with other single-agent regimens.

• Authors: Rhiannon M Doka, Steven E Suter, Michael L Mastromauro, Ashley L Bennett, Paul R Hess
• Journal: Journal of the American Veterinary Medical Association (J Am Vet Med Assoc) Vol. 260 Issue 14 Pg. 1827-1833 (09 01 2022) ISSN: 1943-569X [Electronic] United States
• PMID: 36054007 (Publication Type: Journal Article)

Chemical References

• Doxorubicin

Topics

• Dogs
• Animals
• Histiocytic Sarcoma (veterinary)
• Retrospective Studies
• Dog Diseases (diagnosis)
• Doxorubicin (therapeutic use)
• Treatment Outcome